Amlodipine — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Chronic Kidney Disease

• Atorvastatin
• Furosemide
• Lisinopril
• Losartan

Also listed for Hypertension

• Atenolol
• Bisoprolol
• Carvedilol
• Diltiazem

Other medications in Heart & Cardiovascular

• Apixaban
• Azilsartan
• Bempedoic Acid
• Benazepril
• Bosentan
• Bumetanide
• Candesartan
• Cangrelor

About Amlodipine

Amlodipine is primarily used to treat high blood pressure (hypertension) and certain forms of chest pain (angina). High blood pressure, often called the “silent killer,” can lead to serious health problems like heart attack, stroke, and kidney disease if left untreated. Angina, characterized by chest discomfort, is a symptom of coronary artery disease, where blood flow to the heart muscle is restricted. By effectively managing these conditions, amlodipine plays a vital role in improving cardiovascular health and reducing the risk of severe complications.

Amlodipine belongs to a class of medications known as calcium channel blockers. Its mechanism of action involves relaxing blood vessels throughout the body. It does this by blocking calcium from entering the muscle cells of the heart and blood vessel walls. When these cells receive less calcium, the blood vessels relax and widen. This widening reduces the resistance to blood flow, thereby lowering blood pressure. For angina, this relaxation also helps to increase blood supply to the heart muscle, easing chest pain. It's a once-daily medication, making it a convenient option for long-term management.

Without insurance, the cost of amlodipine can vary significantly depending

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Amlodipine is approved for (FDA label)

NORLIQVA is a calcium channel blocker for the treatment of: Hypertension ( 1.1 ) NORLIQVA is indicated for the treatment of hypertension in adults and children 6 years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Coronary Artery Disease ( 1.2 ) Chronic Stable Angina Vasospastic Angina (Prinzmetal's or Variant Angina) Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction <40% 1.1 Hypertension NORLIQVA ® is indicated for the treatment of hypertension, to lower blood pressure in adults and children 6 years of age and older.

Source: Read the full FDA label on DailyMed. Label effective date: February 16, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Amlodipine (FDA label)

Oral Solution: 1 mg/mL clear, pale straw-colored solution with a mixed berry flavor. Oral solution: 1 mg/mL ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 614d974f-51c7-4b18-8171-39eb6e8d4c03. SPL document ID: 4fee8eba-2fa2-4a9c-884a-ccec171e1977. Label effective date: February 16, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Amlodipine (FDA label)

Most common adverse reactions to amlodipine were edema, dizziness, flushing and palpitation which occurred in a dose related manner. Other adverse reactions not clearly dose-related but reported with an incidence >1.0% are fatigue and nausea. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact CMP Pharma, Inc. at 1-844-321-1443 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Amlodipine has been evaluated for safety in more than 11,000 patients in U.S. and foreign clinical trials.

Source: FDA prescribing information (DailyMed). Set ID: 614d974f-51c7-4b18-8171-39eb6e8d4c03. SPL document ID: 4fee8eba-2fa2-4a9c-884a-ccec171e1977. Label effective date: February 16, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Amlodipine (FDA label)

NORLIQVA is contraindicated in patients with sensitivity to amlodipine. Sensitivity to amlodipine ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 614d974f-51c7-4b18-8171-39eb6e8d4c03. SPL document ID: 4fee8eba-2fa2-4a9c-884a-ccec171e1977. Label effective date: February 16, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Amlodipine (FDA label)

Symptomatic hypotension is possible, particularly in patients with severe aortic stenosis. However, acute hypotension is unlikely. ( 5.1 ) Worsening angina and acute myocardial infarction can develop after starting or increasing the dose of NORLIQVA, particularly in patients with severe obstructive coronary artery disease. ( 5.2 ) Titrate slowly in patients with severe hepatic impairment. ( 5.3 ) 5.1 Hypotension Symptomatic hypotension is possible, particularly in patients with severe aortic stenosis.

Source: FDA prescribing information (DailyMed). Set ID: 614d974f-51c7-4b18-8171-39eb6e8d4c03. SPL document ID: 4fee8eba-2fa2-4a9c-884a-ccec171e1977. Label effective date: February 16, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Amlodipine (FDA label)

Do not exceed doses greater than 20 mg daily of simvastatin. ( 7.2 ) 7.1 Impact of Other Drugs on Amlodipine CYP3A Inhibitors Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is co-administered with CYP3A inhibitors to determine the need for dose adjustment [see Clinical Pharmacology (12.3) ] . CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. 7.2 Impact of Amlodipine on Other Drugs Simvastatin Co-administration of simvastatin with amlodipine increases the systemic exposure of simvastatin. Limit the dose of simvastatin in patients on amlodipine to 20 mg daily [see Clinical Pharmacology (12.3) ] . Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered.

Source: FDA prescribing information (DailyMed). Set ID: 614d974f-51c7-4b18-8171-39eb6e8d4c03. SPL document ID: 4fee8eba-2fa2-4a9c-884a-ccec171e1977. Label effective date: February 16, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.